[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-access-device\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-access-device":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,37,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":5},"100562505","a-clinical-registry-to-demonstrate-the-safety-and-performance-of-teleflex-vascular-access-devices-100562505",false,"NCT06604039","A Clinical Registry to Demonstrate the Safety and Performance of Teleflex Vascular Access Devices","A Prospective Clinical Registry Evaluating Safety and Performance of Teleflex Vascular Access Devices","VADER","Inclusion Criteria:\n\n* Subjects will undergo a procedure that will include use of a Teleflex device covered by this Research.\n* Subject is willing and capable of providing informed consent and\u002For give approval to collect, store and process limited health information by the Sponsor; or such consent is provided by a legally designated representative if required by local law or regulation.\n* Subjects is able to read and understand English or Spanish languages\n\nExclusion Criteria:\n\n* Subject is currently participating in another clinical Registry or investigation that may confound the results of this Registry.\n* Subject was previously failed screening or was enrolled in this clinical Registry.\n* Subject is imprisoned\n* Subject is cognitively impaired and unable to provide informed consent","ALL",{"count":19,"type":20},2500,"ESTIMATED","OBSERVATIONAL","The general objective of Teleflex's Vascular Access Device Registry (VADER) is to provide high-quality Level 3 (or better) data on the performance, safety and clinical benefits of Teleflex's vascular access devices when used in a real-world setting",[24],"Vascular Access Device","RECRUITING","2025-08-01",{"date":28,"type":29},"2025-08-07","ACTUAL",{"date":31,"type":29},"2024-12-08",{"date":33,"type":20},"2034-12-07",{"name":35,"class":36},"Teleflex","INDUSTRY",{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":17,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":59,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100588663","reduction-of-complications-associated-with-picc-management-100588663","NCT06944327","Reduction of Complications Associated With PICC Management","Reduction of Complications Associated With PICC Management. Randomization in Care.","PICC managemen","Inclusion Criteria:\n\n* be over 18 years of age\n* accept participation in the study\n* independent patient in the care and management of activities of daily living\n\nExclusion Criteria:\n\n* patient over 18 years of age\n* patient with functional or cognitive limitation\n* patient with mild, moderate or high level of dependence\n* patient does not accept to perform the study\n* patient with device withdrawal prior to 14 days of duration","18 Years",{"count":47,"type":20},460,"INTERVENTIONAL",[50],"NA","The present study aims to analyze different care routes of the peripheral access central venous catheter to assess which alternative allows a moderate reduction in the level of complications associated with prolonged care frequency, due to the reduction of device manipulation.\n\nA high level of patient satisfaction is detected due to the controlled follow-up of the device care, as well as a decrease in the need for transfer to a center for follow-up.\n\nObjective: Identify the type of care frequency for PIVCs most beneficial for the reduction of complications associated with extraluminal device care (thrombosis, phlebitis, accidental removal, obstruction).",[53,54,24,55,56,57,58],"Treatment Outcome","Vascular Access","Vascular Access Complication","Care Delivery","Nurse","Nurse Based Care Management",[60,61,62,63,64,65,66,67],"vascular","vascular access","catheter","central catheter","nurse","vascular access device","management","complication","NOT_YET_RECRUITING","2025-04-23",{"date":71,"type":29},"2025-04-25",{"date":73,"type":20},"2025-10-01",{"date":75,"type":20},"2027-12-31",{"name":77,"class":78},"Fundacion Miguel Servet","OTHER",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":45,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":48,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100582012","phase-3-induction-treatment-for-initially-unresectable-colorectal-liver-metastases-combined-hepatic-arterial-infusion-pump-therapy-with-systemic-therapy-100582012","NCT06857773","Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","Hepatic Arterial Infusion PUMP Chemotherapy Combined With Systemic Therapy Versus Systemic Therapy Alone as Induction Therapy for Initially Unresectable Colorectal Liver Metastases: a Randomised Controlled Trial","PUMP-IT RCT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed colorectal adenocarcinoma.\n* Unresectable synchronous CRLM according to a National Liver Panel (CT-scan obtained ≤ 4 weeks prior to registration).\n* No extrahepatic metastases. Patients with small (≤ 10 mm) extrahepatic lesions that are not clearly suspicious of metastases are eligible.\n* No previous systemic therapy for colorectal cancer.\n* Positioning of a catheter for HAIP chemotherapy is technically feasible based on imaging. The default site for the catheter insertion is the gastroduodenal artery (GDA). Accessory or aberrant hepatic arteries are no contra-indication for catheter implantation. The GDA should have at least one branch to the liver. Accessory or aberrant hepatic arteries should be ligated to allow for cross perfusion to the entire liver through intrahepatic shunts. Patients with celiac trunk stenosis are not eligible. Patients with both a replaced right and replaced left hepatic artery are not eligible.\n* ECOG performance status 0 or 1.\n* Life expectancy of at least 12 weeks.\n* Known mutation status of RAS and BRAFV600E.\n* Primary tumour in situ and resectable without neoadjuvant therapy.\n* Patient is eligible for surgery.\n* Patient is eligible for doublet chemotherapy.\n* Laboratory requirements: i.e. adequate bone marrow, liver and renal function (obtained within 15 days prior to registration).\n\n  * Hb ≥ 5.5 mmol\u002FL\n  * absolute neutrophil count (ANC) ≥1.5 x 109\u002FL\n  * platelets ≥100 x 109\u002FL\n  * total bilirubin ≤ 1.5 times the upper limit of normal (ULN)\n  * ASAT\u002FAST ≤ 5 x ULN\n  * ALAT\u002FALT ≤ 5 x ULN\n  * alkaline phosphatase ≤ 5 x ULN\n  * Serum creatinine ≤ 1.5 x upper limit of normal or a MDRD (eGFR) ≥ 45 ml\u002Fmin;\n  * Prothrombin time or INR \\\u003C 1.5 x ULN, unless coumarin derivates are used. All patients using coumarin derivates will be treated with LMWH or DOAC instead.\n* Before registration, written informed consent must be given and signed according to ICH\u002FGCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Prior hepatic radiation, resection, or ablation.\n* Any malignancy, comorbidity or condition that interferes with the planned study treatment or the prognosis of CRLM, determined by the treating physician.\n* History of prior malignancy except for the following: (a) malignancy treated with curative intent and with no evidence of active disease present within 3 years prior to inclusion, (b) curatively treated malignancies felt to be at low risk for recurrence by treating physician and MDT, (c) adequately controlled nonmelanomatous skin cancer, (d) adequately treated carcinoma in situ without current evidence of disease.\n* Obstructive primary tumour requiring emergency surgery, primary tumour necessitating a multivisceral resection\u002Fabdominoperineal resection or a rectal tumour requiring preoperative short-course radiotherapy or chemoradiotherapy for local tumour control.\n* MMR deficiency.\n* DPD-deficiency.\n* Pregnant or lactating women.\n* Serious concomitant systemic disorders that would compromise the safety of the patient or his\u002Fher ability to complete the study, at the discretion of the investigator.\n* Organ allografts requiring immunosuppressive therapy.\n* Serious non-healing wound, ulcer, or bone fracture.\n* Chronic treatment with corticosteroids (dose of ≥ 10 mg\u002Fday methylprednisolone equivalent excluding inhaled steroids).\n* Known serious infections (uncontrolled or requiring treatment).\n* History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for HAIP-SYST or standard systemic therapy.\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.\n* Underlying liver disease including liver fibrosis and cirrhosis",{"count":88,"type":20},306,[90],"PHASE3","The goal of this randomized clinical trial is to investigate induction treatment with Hepatic Arterial Infusion Pump therapy combined with systemic therapy (HAIP-SYST) in chemotherapy-naive patients with unresectable colorectal liver metastases without extrahepatic disease. The main question it aims to answer is if combined HAIP-SYST improves survival compared to induction treatment with systemic therapy alone. Patients in the control arm will receive systemic therapy according to standard of care.\n\nStudy procedures experimental arm\n\n* Surgery for pump placement and resection of the primary tumor\n* Pre- and postoperative imaging (CT-anghiography, 99mTc-MAA scintigraphy)\n* Induction treatment with hepatic arterial infusion pump therapy with Floxuridine combined with systemic therapy\n\nStudy procedures both arms\n\n* Evaluation of resectability status by a National Liver Panel with surgeons and radiologists\n* Questionnaires for Quality of Life",[93,94,95,24],"Colorectal Neoplasms","Floxuridine","Liver Metastases","2025-02-27",{"date":98,"type":29},"2025-03-04",{"date":100,"type":29},"2024-11-21",{"date":102,"type":20},"2035-01",{"name":104,"class":78},"The Netherlands Cancer Institute",1]